ResMed Inc. closed 18.89% short of its 52-week high of $263.05, which the company reached on January 30th.

RMD recently launched its home sleep apnea test, NightOwl, across the United States. NightOwl is an FDA-cleared home sleep apnea test (HSAT), designed to offer healthcare providers a simplified, ...

NightOwl is now widely available across the United States. Individuals interested in NightOwl should speak with their healthcare provider for more information. To learn more, visit: https://www.resmed ...

ResMed (NYSE:RMD) launched NightOwl™, a home sleep apnea test that enhances user convenience with a small fingertip sensor and cloud data evaluation. Despite the broader market reacting negatively to ...

Let's see which of these two names could be best buys. The post Should I buy Fisher & Paykel or ResMed shares? appeared first ...

Shares of ResMed Inc. RMD advanced 1.78% to $223.85 Monday, on what proved to be an all-around favorable trading session for ...

NightOwl, an FDA-cleared home sleep apnea test (HSAT) offers a simplified, accurate, efficient way to diagnose obstructive sleep apnea (OSA). It adds another offering to Resmed’s portfolio, which is ...

ResMed Inc. (NYSE:RMD – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the sixteen ratings firms that are covering the company, Marketbeat.com reports. One equities ...

ResMed Inc. (NYSE:RMD – Get Free Report)’s stock price traded down 4.3% during mid-day trading on Wednesday after an insider sold shares in the company.The stock traded as low as $221.34 and ...

People have complained about Apple Vision Pro's weight, so ResMed built the Kontor Head Strap that helps by adding ...

Morgan Stanley analyst David Bailey initiated coverage of ResMed (RMD) with an Overweight rating and $280 price target The company has a market-leading position in the obstructive sleep apnea ...